about
Molecular and cell-based therapies for muscle degenerations: a road under constructionNoncoding RNAs: emerging players in muscular dystrophiesNutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the ConjecturePregnancy-induced amelioration of muscular dystrophy phenotype in mdx mice via muscle membrane stabilization effect of glucocorticoidNight Activity Reduction is a Signature Physiological Biomarker for Duchenne Muscular Dystrophy Dogs.Quantitative ultrasound: measurement considerations for the assessment of muscular dystrophy and sarcopenia.MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples.Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by KinectSerum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy.Framing optional genetic testing in the context of mandatory newborn screening tests.Large-scale serum protein biomarker discovery in Duchenne muscular dystrophyClinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy.A first-line diagnostic assay for limb-girdle muscular dystrophy and other myopathies.Trends in steroid therapy for Duchenne muscular dystrophy in JapanFeeding and Swallowing Disorders in Pediatric Neuromuscular Diseases: An Overview.Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients.Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells.Fetal stem cells and skeletal muscle regeneration: a therapeutic approach.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Evolving paradigms in clinical pharmacology and therapeutics for the treatment of Duchenne muscular dystrophy.Outcomes of Hospitalised Muscular Dystrophy Patients.Understanding the process of fibrosis in Duchenne muscular dystrophy.Circulating miRNAs are generic and versatile therapeutic monitoring biomarkers in muscular dystrophies.Hydrogel biomaterials and their therapeutic potential for muscle injuries and muscular dystrophies.Sulforaphane mitigates muscle fibrosis in mdx mice via Nrf2-mediated inhibition of TGF-β/Smad signaling.[Current care strategies for Duchenne muscular dystrophy].Muscle-specific microRNA-206 targets multiple components in dystrophic skeletal muscle representing beneficial adaptations.NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
P2860
Q24568176-AC276708-163B-4983-A42C-024C4D58D69BQ26996781-7E77B2AE-6269-40D6-97EF-F31989738902Q28072269-57B16AD6-01E1-4EF0-9675-9EEF95E77A63Q28544401-5FCCDB0E-54B3-4C72-B940-D2CE6C81822CQ28596730-B66B4677-338F-44AD-B694-1091CA56790DQ33891261-03DE234B-AC57-40C0-BC20-6B1FB1677D12Q34234134-810E3749-A789-47FC-A944-B9D7E0F404BBQ34517198-EC82F197-27BF-469E-BADE-F963697ED955Q35234158-F3F0151D-41A5-49EC-9594-E9E8C49E19B3Q35677888-3E0408C1-6FB3-48BC-AF56-DAF67E7A896AQ35740280-AA019A0A-7F59-4439-90B8-B2B207951759Q36073309-ED3DB8D3-E5B7-4EEF-807B-20AF301DF63AQ36410147-31D4AA37-AE1A-44F2-B329-2DDEEB39F63AQ37286757-1E74D857-0EAF-4832-8ABD-97390544808AQ37420460-DA387015-448D-471E-AEB4-DDB586EE6FBBQ37589746-4A40B7F3-5567-4154-A523-287D34FDD32AQ37589749-283DF10A-AC20-4D53-8184-396BA0504213Q38193799-503D603E-5E57-4DFE-997B-B64E0980319AQ38249175-7CD63AAF-03D9-4134-8A02-4A731B80D588Q38302852-106C896C-9861-4C74-B960-0B9A7EF658D8Q38806441-8CB9648B-0AD3-4BA0-A760-6134C03CBD00Q38879165-2BD66576-0F94-42BB-876A-A2266B0F9B3AQ39699112-C6C1583A-0FF4-4A0A-9514-F7249B5F252AQ42209543-7C75C55A-4ED6-435F-AF17-55BFE2E3D0E5Q48223753-63F54368-085D-4C9B-80F7-CFB27219D0FDQ50280511-5B56C360-681E-47B4-A1E2-46FC72277BFAQ50657212-B2808713-75E5-48B2-9876-4BEB0280226DQ51243987-3801D459-9B24-4921-A330-67E93E9EAB60Q58549842-11E45092-3330-412A-A8C3-A3BD5AE93D24
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic advances in muscular dystrophy
@en
Therapeutic advances in muscular dystrophy.
@nl
type
label
Therapeutic advances in muscular dystrophy
@en
Therapeutic advances in muscular dystrophy.
@nl
prefLabel
Therapeutic advances in muscular dystrophy
@en
Therapeutic advances in muscular dystrophy.
@nl
P2860
P921
P356
P1433
P1476
Therapeutic advances in muscular dystrophy
@en
P2093
Doris G Leung
Kathryn R Wagner
P2860
P304
P356
10.1002/ANA.23989
P5008
P577
2013-09-01T00:00:00Z